Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription 10.02.2025 4 Am J Hematol 2 Ann Hematol 3 Blood 1 BMC Cancer 1 Cancer 1 Exp Hematol 2 J Clin Oncol 1 J Pediatr Hematol Oncol 1 Leuk Res 6 Leukemia

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. 
   Correction to "Secondary-Type Mutations Do Not Impact Prognosis in Acute Myelogenous Leukemia AML With Mutated NPM1".
   Am J Hematol. 2025 Feb 5. doi: 10.1002/ajh.27629.
   PubMed        
   
   
2. SHIMONY S, Garcia JS
   Sharpening the Tools to Get the Edge on Leukemia.
   Am J Hematol. 2025 Feb 4. doi: 10.1002/ajh.27622.
   PubMed        
   
   
3. CHEN EC, Shimony S, Luskin MR, Stone RM, et al
   Biology and Management of Acute Myeloid Leukemia With Mutated NPM1.
   Am J Hematol. 2025 Feb 4. doi: 10.1002/ajh.27600.
   PubMed         Abstract available
   
   
4. BRUNO JE, Herne CA, Baran AM, VanDerMeid KR, et al
   Treatment of Relapsed/Refractory CLL Patients With PI3Kdelta Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance.
   Am J Hematol. 2025;100:523-526.
   PubMed         Abstract available
   
   

   
   Ann Hematol

5. SHUMILOV E, Mazzeo P, Trautmann M, Levien L, et al
   Functional apoptosis profiling reveals vulnerabilities in T-cell large granular lymphocytic leukemia.
   Ann Hematol. 2025 Feb 6. doi: 10.1007/s00277-025-06230.
   PubMed         Abstract available
   
   
6. SHAFIEIZADEGAN S, Aberuyi N, Rahgozar S
   The molecular impact of miR-326 in acute lymphoblastic leukemia and its cross talk with P53.
   Ann Hematol. 2025 Feb 5. doi: 10.1007/s00277-024-06181.
   PubMed         Abstract available
   
   

   
   Blood

7. MANTZARIS I, Goldfinger M, Uriel M, Shastri A, et al
   Venetoclax plus Daunorubicin and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia: Results of a Phase 1b Study.
   Blood. 2025 Feb 7:blood.2024026700. doi: 10.1182/blood.2024026700.
   PubMed         Abstract available
   
   
8. SHEN Q, Hu S
   Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements.
   Blood. 2025;145:652.
   PubMed        
   
   
9. FISKUS W, Mill CP, Bose P, Masarova L, et al
   Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.
   Blood. 2025;145:612-624.
   PubMed         Abstract available
   
   

   
   BMC Cancer

10. XIE F, Zhang TJ, Zhang XL, Xu ZJ, et al
    Identification of HOXA9 methylation as an epigenetic biomarker predicting prognosis and guiding treatment choice in acute myeloid leukemia.
    BMC Cancer. 2025;25:215.
    PubMed         Abstract available
    
    

    
    Cancer

11. LUSKIN MR, Yin J, Lozanski G, Curran E, et al
    Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.
    Cancer. 2025;131:e35750.
    PubMed         Abstract available
    
    

    
    Exp Hematol

12. DE GROOT AP, Nguyen H, Pouw JS, Weersing E, et al
    CBX7 inhibitors affect H3K9 methyltransferase-regulated gene repression in leukemic cells.
    Exp Hematol. 2025;142:104691.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

13. KATO M, Okamoto Y, Imamura T, Kada A, et al
    JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL.
    J Clin Oncol. 2025;43:567-577.
    PubMed         Abstract available
    
    
14. ROLOFF GW, Aldoss I, Kopmar NE, Lin C, et al
    Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
    J Clin Oncol. 2025;43:558-566.
    PubMed         Abstract available
    
    

    
    J Pediatr Hematol Oncol

15. STEINHERZ PG, Mauguen A, Suser S, Ramaswamy K, et al
    Treatment of T-cell Leukemia/Lymphoma in Children and Young Adults With the Memorial Sloan Kettering Cancer Center New York IIB Protocol.
    J Pediatr Hematol Oncol. 2025 Jan 28. doi: 10.1097/MPH.0000000000002999.
    PubMed         Abstract available
    
    

    
    Leuk Res

16. YOSHIDA N, Hida A, Sakata R
    Trends of changes in human T-cell leukemia virus type 1 epidemiology in Japan and globally.
    Leuk Res. 2025;150:107654.
    PubMed         Abstract available
    
    

    
    Leukemia

17. OKABE S, Arai Y, Gotoh A
    Correspondence to: "Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations", Curik N et al. Leukemia. 2024; 38: 1415-1418.
    Leukemia. 2025 Feb 6. doi: 10.1038/s41375-025-02521.
    PubMed        
    
    
18. SU Y, Han Z, Ji Y, Liu A, et al
    Patterns and variations of copy number alterations in acute myeloid leukemia: insights from the LeukAtlas database.
    Leukemia. 2025 Feb 2. doi: 10.1038/s41375-025-02514.
    PubMed         Abstract available
    
    
19. FALINI B, Sorcini D, Perriello VM, Sportoletti P, et al
    Functions of the native NPM1 protein and its leukemic mutant.
    Leukemia. 2025;39:276-290.
    PubMed         Abstract available
    
    
20. YANG S, Zhang X, Gale RP, Huang X, et al
    Is there really an accelerated phase of chronic myeloid leukaemia at presentation?
    Leukemia. 2025;39:391-399.
    PubMed         Abstract available
    
    
21. CALVO J, Naguibneva I, Kypraios A, Gilain F, et al
    High CD44 expression and enhanced E-selectin binding identified as biomarkers of chemoresistant leukemic cells in human T-ALL.
    Leukemia. 2025;39:323-336.
    PubMed         Abstract available
    
    
22. ORTI G, Peczynski C, Boreland W, O'Reilly M, et al
    Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.
    Leukemia. 2025;39:431-437.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.